Document and Entity Information |
Mar. 29, 2023 |
|---|---|
| Cover [Abstract] | |
| Security Exchange Name | NASDAQ |
| Amendment Flag | true |
| Entity Central Index Key | 0001780097 |
| Document Type | 8-K/A |
| Document Period End Date | Mar. 29, 2023 |
| Entity Registrant Name | Baudax Bio, Inc. |
| Entity Incorporation State Country Code | PA |
| Entity File Number | 001-39101 |
| Entity Tax Identification Number | 47-4639500 |
| Entity Address, Address Line One | 490 Lapp Road |
| Entity Address, City or Town | Malvern |
| Entity Address, State or Province | PA |
| Entity Address, Postal Zip Code | 19355 |
| City Area Code | (484) |
| Local Phone Number | 395-2470 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.01 |
| Trading Symbol | BXRX |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | true |
| Amendment Description | On March 31, 2023, Baudax Bio, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K) to disclose that (i) the Company entered into that certain Amendment No. 5 and Consent to Credit Agreement by and among the Company, Baudax Bio N.A. LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K. The purpose of this Amendment No. 1 is solely to file the Transfer Agreement as Exhibit 10.3. |